EUVIMEDEUVIMED entdecken
Crossref

Drug-Loaded Hybrid Tissue Engineered Heart Valve with Antithrombosis and Immunomodulation Performance

Shaoge Bai, Bangquan Wei, Lepeng Chen, Xueyu Huang, Kaiyang Huang, Li Yang, Cheng Zheng, Yunbing Wang iD

ACS Applied Materials & Interfaces · 2025

DOI: 10.1021/acsami.4c22022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2025. Verfasst von Shaoge Bai und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Engineering Research Center for Biomaterials& College of Biomedical Engineering, Sichuan University, Chengdu 610065, China. Hauptthemen laut MEDLINE: Tissue Engineering, Heart Valve Prosthesis, Thrombosis, Curcumin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Chinese Academy of Medical Sciences, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High thrombogenicity and shortened lifespan have limited the application of mechanical valves and bioprosthetic valves, respectively. Tissue engineering heart valve (TEHV) holds significant potential as a favorable prosthetic valve to overcome the limitations of the current prosthetic valves, featuring the capabilities of self-pairing and adaptive remodeling. However, TEHVs, mainly fabricated from decellularized xenogeneic heart valves (DHV), still have challenges such as thrombosis, inferior endothelialization, and immune responses. Herein, a drug-loaded glycoprotein-like network hybrid TEHV (OHSC-V) was engineered through the one-pot hybridization of DHV, oxidized HA (OHA), phenylboronic acid grafted silk fibroin (SF-PBA), and curcumin (Cur), where OHA served as a biocompatible backbone to cross-link the DHV and the conjugate of SF-PBA and Cur. With the introduction of the multifunctional drug-loaded glycoprotein-like network, OHSC-V not only effectively inhibited the adsorption of plasma proteins, blood cells, platelets, and thrombosis but also facilitated the endothelialization of TEHV. Furthermore, the OHSC-V eliminated the reactive oxygen species and responsively released Cur to modulate the immune responses. Moreover, the calcification degree of hybrid TEHVs was markedly lower than that of glutaraldehyde cross-linked DHV after 90 days of implantation. Overall, OHSC-V demonstrated enhanced performance of antithrombosis, endothelialization, immunomodulation, and anticalcification, showcasing the further potential for application exploration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tissue EngineeringHeart Valve ProsthesisThrombosisCurcuminHeart ValvesAnimalsHumansBoronic AcidsImmunomodulationFibroins

Stichwörter der Autor:innen

antithrombosisendothelializationglycoprotein-like networkimmunomodulationtissue engineered heart valve

Substanzen

CurcuminBoronic AcidsFibroinsbenzeneboronic acid

Autor:innen und Institutionen

  • National Engineering Research Center for Biomaterials& College of Biomedical Engineering, Sichuan University, Chengdu 610065, China.
  • Research Unit of Minimally Invasive Treatment of Structural Heart Disease, Chinese Academy of Medical Sciences, No.: 2021RU013, Chengdu 610064, China.

ORCID-Profile: Yunbing Wang

Förderung

  • National Key Research and Development Program of China
  • Chinese Academy of Medical Sciences
  • National Natural Science Foundation of China

Zitieren

APA

Bai, S., Wei, B., Chen, L., Huang, X., Huang, K., Yang, L., Zheng, C., & Wang, Y. (2025). Drug-Loaded Hybrid Tissue Engineered Heart Valve with Antithrombosis and Immunomodulation Performance. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.4c22022

Vancouver

Bai S, Wei B, Chen L, Huang X, Huang K, Yang L, et al. Drug-Loaded Hybrid Tissue Engineered Heart Valve with Antithrombosis and Immunomodulation Performance. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.4c22022

BibTeX
@article{Bai2025,
  author = {Bai, Shaoge and Wei, Bangquan and Chen, Lepeng and Huang, Xueyu and Huang, Kaiyang and Yang, Li and Zheng, Cheng and Wang, Yunbing},
  title = {Drug-Loaded Hybrid Tissue Engineered Heart Valve with Antithrombosis and Immunomodulation Performance},
  journal = {ACS Applied Materials & Interfaces},
  year = {2025},
  doi = {10.1021/acsami.4c22022}
}
Kostenlos starten →